Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company's products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company's products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:HPTX
CUSIP44915N10
WebN/A
Phone+1-650-7457802
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins23.13%
Return on Equity21.30%
Return on Assets15.42%
Miscellaneous
EmployeesN/A
Outstanding Shares20,980,000
Market Cap$964.29
Horizon Therapeutics (NASDAQ:HPTX) Frequently Asked Questions
What is Horizon Therapeutics' stock symbol?
Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HPTX."
How were Horizon Therapeutics' earnings last quarter?
Horizon Therapeutics Inc (NASDAQ:HPTX) announced its quarterly earnings data on Thursday, February, 26th. The biopharmaceutical company reported $0.47 EPS for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.67. The biopharmaceutical company had revenue of $30.80 million for the quarter, compared to the consensus estimate of $24.60 million. Horizon Therapeutics had a return on equity of 21.30% and a net margin of 23.13%. The business's revenue was up 65.6% on a year-over-year basis. View Horizon Therapeutics' Earnings History.
What is the consensus analysts' recommendation for Horizon Therapeutics?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Has Horizon Therapeutics been receiving favorable news coverage?
Media headlines about HPTX stock have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Horizon Therapeutics earned a daily sentiment score of 0.08 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Horizon Therapeutics?
Shares of HPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Horizon Therapeutics' stock price today?
One share of HPTX stock can currently be purchased for approximately $45.99.
How big of a company is Horizon Therapeutics?
Horizon Therapeutics has a market capitalization of $964.29 million.
How can I contact Horizon Therapeutics?
Horizon Therapeutics' mailing address is 2000 Sierra Point Pkwy Ste 400, BRISBANE, CA 94005-1849, United States. The biopharmaceutical company can be reached via phone at +1-650-7457802.
MarketBeat Community Rating for Horizon Therapeutics (NASDAQ HPTX)
MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote "Outperform" if you believe HPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
